Italia markets closed

Aclaris Therapeutics, Inc. (0H8T.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
14,70+1,61 (+12,34%)
Alla chiusura: 03:53PM BST

Aclaris Therapeutics, Inc.

640 Lee Road
Suite 200
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Settore/i
Settore
Impiegati a tempo pieno72

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Neal S. Walker D.O.Co-Founder, CEO & Director965,59kN/D1970
Mr. Frank RuffoCo-Founder, CFO , Sec. & Treasurer590,85kN/D1966
Dr. Joseph MonahanChief Scientific Officer515,3kN/DN/D
Dr. Douglas J. Manion Frcp(C), M.D.Pres & COON/DN/D1961
Mr. Matthew Rothman J.D.VP of Legal & ComplianceN/DN/DN/D
Dr. Jon Jacobsen Ph.D.Sr. VP of ChemistryN/DN/DN/D
Dr. Paul S. Changelian Ph.D.Sr. VP of BiologyN/DN/DN/D
Mr. James LoeropChief Bus. OfficerN/DN/D1965
Dr. Ian Anderson Ph.D.Exec. VP of Translational R&DN/DN/DN/D
Dr. Gail Cawkwell M.D., Ph.D.Chief Medical OfficerN/DN/D1962
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Aclaris Therapeutics, Inc. al 1 settembre 2022 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.